NCT05465317View on ClinicalTrials.gov

Evaluating Comparative Effectiveness of Empagliflozin in Type 2 Diabetes Population With and Without Chronic Kidney Disease

CompletedOBSERVATIONAL
Enrollment

62,197

Participants

Timeline

Start Date

August 8, 2022

Primary Completion Date

May 2, 2023

Study Completion Date

May 2, 2023

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Empagliflozin

Empagliflozin

DRUG

Dipeptidyl Peptidate-4 inhibitors

Dipeptidyl Peptidate-4 inhibitors

Trial Locations (1)

27707

Duke Clinical Research Institute, Durham

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT05465317 - Evaluating Comparative Effectiveness of Empagliflozin in Type 2 Diabetes Population With and Without Chronic Kidney Disease | Biotech Hunter | Biotech Hunter